Latest Nupathe Inc (PATH) Headlines
Teva Completes Tender Offer for NuPathe Inc. Shares
Business Wire - Fri Feb 21, 8:15AM CST
--80% of Shares Tendered
Will Teva Pharmaceutical Industries LTD Shares Wilt Under the Federal Microscope?
David Williamson, The Motley Fool - Motley Fool - Mon Feb 10, 8:35PM CST
Shares of Teva Pharmaceutical Industries were down about 1% after the company disclosed a federal investigation into its marketing practices. Both Teva's primary money-maker, Copaxone, which treats multiple sclerosis, and Azilect, used in the...
Those Leaving PDP Are Nomads - -Maku
by Ben Agande - All Africa Global Media - Thu Feb 06, 2:08AM CST
Minister of information and Supervising minister of Defence, Labaran Maku, Wednesday, described those who have defected from the ruling Peoples Democratic Party to the opposition All Progressives Congress as nomads who are always on the move from one party to the other.
Endo Health Scores Legal Victory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:02PM CST
Endo won a legal battle on Frova.
Teva to Acquire NuPathe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 3:58PM CST
Teva Pharmaceutical announced that it has entered into a definitive agreement to acquire NuPathe Inc.
Delta and Dow are big market movers
AP - Tue Jan 21, 3:23PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Teva (TEVA) Acquires NuPathe (PATH) for $144 Million
at The Street - Tue Jan 21, 3:14PM CST
Teva (TEVA) will pay $3.65 in cash per share of NuPathe (PATH).
Teva Snags NuPathe From Endo Health for $144 Million
Justin Loiseau, The Motley Fool - Motley Fool - Tue Jan 21, 12:47PM CST
Teva Pharmaceutical Industries Ltd. announced today that it will buy NuPathe for $144 million upfront, with the possibility of adding on approximately $124 million more if NuPathe achieves certain sales goals. NuPathe's main draw is its...
NuPathe Picks Teva as Merger Partner
at The Street - Tue Jan 21, 11:43AM CST
Teva Pharmaceutical Industries won a bid to purchase Malvern, Pa.-based NuPathe with an offer that came in at only $9 million more than its M&A rival, Endo Health Solutions.
NuPathe Terminates Agreement With Endo and Enters Into Agreement to Be Acquired by Teva
Marketwire - Tue Jan 21, 6:01AM CST
NuPathe Inc. (NASDAQ: PATH) today announced that it has terminated its agreement and plan of merger with Endo Health Solutions Inc. and its Board has withdrawn its recommendation that stockholders accept Endo's offer to acquire all outstanding shares of NuPathe common stock. NuPathe has also entered into an agreement and plan of merger with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) under which Teva will acquire NuPathe for $3.65 per share in cash. In addition to the upfront cash payment, NuPathe stockholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, ZECUITY(R), are achieved over time.
Endo Merger Agreement with NuPathe Terminated
PR Newswire - Tue Jan 21, 6:01AM CST
Endo Health Solutions (Nasdaq: ENDP) today announced that NuPathe Inc. (NASDAQ: PATH) has terminated its merger agreement with Endo. Endo has received a $5 million termination fee from NuPathe.
Teva Expands CNS Specialty Business with Acquisition of NuPathe
Business Wire - Tue Jan 21, 6:00AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq
ATH) for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, ZECUITY(R), are achieved over time.
NuPathe Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Fri Jan 17, 10:31AM CST
Securities lawyers at Deans & Lyons announce an investigation of the board of NuPathe Inc. (NASDAQ: PATH) in connection with a buyout for $2.85 per share. Concerned PATH investors are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Big Changes and Small Moves for Teva Pharmaceutical Industries Ltd.
David Williamson, The Motley Fool - Motley Fool - Sun Jan 12, 2:09PM CST
Teva Pharmaceuticals has been engulfed with turmoil. Its blockbuster MS franchise is facing a new competitive thereat, and the company is staring down the barrel of its patent expiration. Then in October, we saw the surprise departure of...
NuPathe Soars on Teva Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 2:05PM CST
Shares of NuPathe soared 35.6% on Jan 8 after it announced the receipt of an acquisition offer from Teva.
Why NuPathe, Galena Biopharma, and Bitauto Holdings Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 08, 4:15PM CST
It was another day of generally good economic data, but one bad apple spoiled the bunch for the broad-based S&P 500 . Unsurprisingly, U.S. jobs data continues to point toward an improving long-term outlook. The ADP employment report, released...
JC Penney and Micron are big market movers
AP - Wed Jan 08, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why NuPathe Inc. (PATH) Is Up Today
at The Street - Wed Jan 08, 11:44AM CST
NuPathe Inc. (PATH) rose 36% in early morning trading Wednesday after Teva Pharmaceuticals made a bid of $114 million to acquire it.
Endo Health Solutions
at Investor's Business Daily - Thu Jan 02, 5:49PM CST
Endo Health Solutions (ENDP) was downgraded to sell by Cantor Fitzgerald. The specialty drugmaker won't be able to make further cost cuts unless it sells its American Medical Systems unit, and upcoming drug launches will face stiff competition, the...
Teva Completes Tender Offer for NuPathe Inc. Shares
Business Wire - Fri Feb 21, 8:15AM CST
--80% of Shares Tendered
Will Teva Pharmaceutical Industries LTD Shares Wilt Under the Federal Microscope?
David Williamson, The Motley Fool - Motley Fool - Mon Feb 10, 8:35PM CST
Shares of Teva Pharmaceutical Industries were down about 1% after the company disclosed a federal investigation into its marketing practices. Both Teva's primary money-maker, Copaxone, which treats multiple sclerosis, and Azilect, used in the...
Those Leaving PDP Are Nomads - -Maku
by Ben Agande - All Africa Global Media - Thu Feb 06, 2:08AM CST
Minister of information and Supervising minister of Defence, Labaran Maku, Wednesday, described those who have defected from the ruling Peoples Democratic Party to the opposition All Progressives Congress as nomads who are always on the move from one party to the other.
Endo Health Scores Legal Victory - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 5:02PM CST
Endo won a legal battle on Frova.
Teva to Acquire NuPathe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 3:58PM CST
Teva Pharmaceutical announced that it has entered into a definitive agreement to acquire NuPathe Inc.
Delta and Dow are big market movers
AP - Tue Jan 21, 3:23PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Teva (TEVA) Acquires NuPathe (PATH) for $144 Million
at The Street - Tue Jan 21, 3:14PM CST
Teva (TEVA) will pay $3.65 in cash per share of NuPathe (PATH).
Teva Snags NuPathe From Endo Health for $144 Million
Justin Loiseau, The Motley Fool - Motley Fool - Tue Jan 21, 12:47PM CST
Teva Pharmaceutical Industries Ltd. announced today that it will buy NuPathe for $144 million upfront, with the possibility of adding on approximately $124 million more if NuPathe achieves certain sales goals. NuPathe's main draw is its...
NuPathe Picks Teva as Merger Partner
at The Street - Tue Jan 21, 11:43AM CST
Teva Pharmaceutical Industries won a bid to purchase Malvern, Pa.-based NuPathe with an offer that came in at only $9 million more than its M&A rival, Endo Health Solutions.
NuPathe Terminates Agreement With Endo and Enters Into Agreement to Be Acquired by Teva
Marketwire - Tue Jan 21, 6:01AM CST
NuPathe Inc. (NASDAQ: PATH) today announced that it has terminated its agreement and plan of merger with Endo Health Solutions Inc. and its Board has withdrawn its recommendation that stockholders accept Endo's offer to acquire all outstanding shares of NuPathe common stock. NuPathe has also entered into an agreement and plan of merger with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) under which Teva will acquire NuPathe for $3.65 per share in cash. In addition to the upfront cash payment, NuPathe stockholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, ZECUITY(R), are achieved over time.
Endo Merger Agreement with NuPathe Terminated
PR Newswire - Tue Jan 21, 6:01AM CST
Endo Health Solutions (Nasdaq: ENDP) today announced that NuPathe Inc. (NASDAQ: PATH) has terminated its merger agreement with Endo. Endo has received a $5 million termination fee from NuPathe.
Teva Expands CNS Specialty Business with Acquisition of NuPathe
Business Wire - Tue Jan 21, 6:00AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that it has entered into a definitive agreement under which Teva will acquire NuPathe Inc. (Nasdaq
ATH) for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, ZECUITY(R), are achieved over time. NuPathe Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Fri Jan 17, 10:31AM CST
Securities lawyers at Deans & Lyons announce an investigation of the board of NuPathe Inc. (NASDAQ: PATH) in connection with a buyout for $2.85 per share. Concerned PATH investors are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen
PR Newswire - Mon Jan 13, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Big Changes and Small Moves for Teva Pharmaceutical Industries Ltd.
David Williamson, The Motley Fool - Motley Fool - Sun Jan 12, 2:09PM CST
Teva Pharmaceuticals has been engulfed with turmoil. Its blockbuster MS franchise is facing a new competitive thereat, and the company is staring down the barrel of its patent expiration. Then in October, we saw the surprise departure of...
NuPathe Soars on Teva Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 2:05PM CST
Shares of NuPathe soared 35.6% on Jan 8 after it announced the receipt of an acquisition offer from Teva.
Why NuPathe, Galena Biopharma, and Bitauto Holdings Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 08, 4:15PM CST
It was another day of generally good economic data, but one bad apple spoiled the bunch for the broad-based S&P 500 . Unsurprisingly, U.S. jobs data continues to point toward an improving long-term outlook. The ADP employment report, released...
JC Penney and Micron are big market movers
AP - Wed Jan 08, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why NuPathe Inc. (PATH) Is Up Today
at The Street - Wed Jan 08, 11:44AM CST
NuPathe Inc. (PATH) rose 36% in early morning trading Wednesday after Teva Pharmaceuticals made a bid of $114 million to acquire it.
Endo Health Solutions
at Investor's Business Daily - Thu Jan 02, 5:49PM CST
Endo Health Solutions (ENDP) was downgraded to sell by Cantor Fitzgerald. The specialty drugmaker won't be able to make further cost cuts unless it sells its American Medical Systems unit, and upcoming drug launches will face stiff competition, the...
